• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 1-A-W filed by Tivic Health Systems Inc.

    9/17/25 4:30:01 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $TIVC alert in real time by email
    1-A-W 1 tivic_1aw.htm OFFERING STATEMENT WITHDRAWAL

    Tivic Health Systems, Inc.

    47865 Lakeview Blvd.

    Fremont, CA 94538

    (888) 276-6888

     

    September 17, 2025

     

    VIA EDGAR  

     

    United States Securities and Exchange Commission

    Division of Corporation Finance

    100 F. Street, N.E.

    Washington, D.C. 20549

     

      Re: Tivic Health Systems, Inc.
        Request for Withdrawal of Offering Statement on Form 1-A
        File No. 024-12489

     

    Ladies and Gentlemen:

     

    In accordance with Rule 259 under the Securities Act of 1933, as amended, Tivic Health Systems, Inc., a Delaware corporation (the “Company”), hereby respectfully requests the immediate withdrawal of its Offering Statement on Form 1-A (File. No. 024-12489), together with all exhibits and amendments thereto (collectively, the “Offering Statement”), which originally was filed with the Securities and Exchange Commission (the “Commission”) on August 16, 2024.

     

    The Company is requesting the consent of the Commission to the withdrawal of the Offering Statement as the Company has decided not to pursue the offering. The Offering Statement has not been declared qualified by the Commission, and no securities have been sold thereunder.

     

    Should you have any questions regarding this request for withdrawal, or if you require any additional information, please contact Caitlin M. Murphey, Esq. of Snell & Wilmer L.L.P. by telephone at (858) 910-4773.

     

     

    Very truly yours,

     

    Tivic Health Systems, Inc.

     

    By: /s/ Jennifer Ernst                            

    Name: Jennifer Ernst

    Title: Chief Executive Officer

     

     

    Get the next $TIVC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TIVC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TIVC
    SEC Filings

    View All

    SEC Form 1-A-W filed by Tivic Health Systems Inc.

    1-A-W - Tivic Health Systems, Inc. (0001787740) (Filer)

    9/17/25 4:30:01 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form EFFECT filed by Tivic Health Systems Inc.

    EFFECT - Tivic Health Systems, Inc. (0001787740) (Filer)

    9/8/25 12:15:14 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B3 filed by Tivic Health Systems Inc.

    424B3 - Tivic Health Systems, Inc. (0001787740) (Filer)

    9/5/25 5:04:33 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $TIVC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Ernst Jennifer was granted 22,541 shares, increasing direct ownership by 3,193% to 23,247 units (SEC Form 4)

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    9/24/25 8:02:15 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form 4 filed by Chief Financial Officer Wolf Lisa G

    4/A - Tivic Health Systems, Inc. (0001787740) (Issuer)

    8/22/25 8:00:41 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form 4 filed by Chief Operating Officer Handley Michael K

    4/A - Tivic Health Systems, Inc. (0001787740) (Issuer)

    8/22/25 8:00:27 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $TIVC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Presenting on Emerging Growth Conference 86 Day 2 September 25; Register to live stream

    MIAMI, Sept. 24, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 86th Emerging Growth Conference on September 24 & 25, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – TodaySeptember 24, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go b

    9/24/25 7:00:00 AM ET
    $ADVM
    $AIIO
    $BANL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Auto Manufacturing
    Industrials

    Presenting on Emerging Growth Conference 86 Day 1 on September 24; Register to live stream

    MIAMI, Sept. 23, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 86th Emerging Growth Conference on September 24 & 25, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - WednesdaySeptember 24, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered,

    9/23/25 7:00:00 AM ET
    $ADVM
    $AIIO
    $BANL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Auto Manufacturing
    Industrials

    Tivic Health CEO Jennifer Ernst to Present at Emerging Growth's September Virtual Conference

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that the company's CEO will present during the Emerging Growth virtual conference set to take place on September 24 & 25, 2025. WHO: Jennifer Ernst, Chief Executive Officer WHERE: September 25, 2025 WHEN: 11:25AM - 11:55AM Eastern Time Jennifer Ernst, CEO of Tivic, will deliver a formal presentation detailing the company's strategic transformation into the biopharmaceutical sector. This evolution positions Tivic as a unique innovator addressing disease by integrating both the body's biochemical and bioelectronic systems. In February

    9/22/25 8:30:00 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $TIVC
    Leadership Updates

    Live Leadership Updates

    View All

    Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team

    Handley Joins as President of Tivic Biopharma and Chief Operating Officer of Tivic Health Following Its Licensing of Strategic Biopharma Assets From Statera Biopharma Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma, Inc., has joined Tivic Health as the President of Tivic Biopharma, a newly formed division of Tivic Health. Additionally, he will assume the role of Chief Operating Officer of Tivic Health and will work closely with the CEO and other leadership team members to develop and operationalize company-wide strategies. His key responsi

    2/24/25 8:15:00 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tivic Health Appoints Lisa Wolf as Interim Chief Financial Officer

    Kimberly Bambach, Ms. Wolf's predecessor, continues with Tivic as advisor focused on strategic transactions and special projects Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to announce the appointment of Lisa Wolf as Interim Chief Financial Officer (CFO) of the company, effective October 1, 2024. Ms. Wolf will take over from Kimberly Bambach, who has served as the company's interim CFO since April 2023. Ms. Bambach will continue with Tivic in an advisory role for strategic transactions and other special projects. "Lisa has served as a senior member of Tivic's finance team for over two

    9/13/24 5:29:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tivic Announces Appointment of New Interim CFO, Kimberly Bambach, and Strategic Advisor to the Board, Christine Valauri

    Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the appointment of veteran Kimberly Bambach to serve as Interim Chief Financial Officer of the company and the engagement of Christina Valauri as a strategic advisor to the Board of Directors. These additions aim to strengthen the company's financial foundation and bring growth and M&A expertise to the team. Ms. Bambach brings over 30 years of financial leadership experience in both public and private companies across industries. Her background includes financial leadership in medical and retail markets, manufacturing, wholesale distrib

    5/1/23 9:30:00 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $TIVC
    Financials

    Live finance-specific insights

    View All

    Tivic Reports Second Quarter 2025 Financial Results

    Company advances its TLR5 agonist program and prepares to report VNS clinical data Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced financial results for the second quarter and six months ended June 30, 2025. "We have established a strong foundation for Tivic's strategic transformation with our expansion into biopharmaceuticals, making us unique in treating disease by addressing both the body's biochemical and bioelectronic systems," stated Tivic CEO Jennifer Ernst. "To maximize our focus on the compelling, late-stage clinical pipeline, we have increasingly shifted resources away from consumer healthtech and are now planning to exit

    8/14/25 4:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tivic Health to Report Second Quarter 2025 Financial Results on August 14th Via Conference Call and Webcast

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today announced that it will report its second quarter results for 2025 via pre-recorded conference call and webcast on Thursday, August 14, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 793820 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/52776 About Tivic Health Systems, Inc. Tivic Health seeks to treat underserved medical conditions through biochemical and bioelectric therapies that modulate patients' immune system. The company's

    8/7/25 8:30:00 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tivic Reports First Quarter 2025 Financial Results and Provides Updates on Business Transformation

    Pre-recorded Conference Call to Follow at 1:30 p.m. PDT/4:30 p.m. EDT Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced financial results for the first quarter ended March 31, 2025 and outlined operational highlights based on its newly expanded clinical pipeline. "This is a defining time for the company. During the quarter we initiated a significant strategic shift, dramatically expanding Tivic's clinical pipeline for restoring immune system health," stated Tivic CEO Jennifer Ernst. "In February, we executed a comprehensive worldwide exclusive licensing agreement for the Phase III TLR5 agonist, Entolimod and its molecular derivative, Ent

    5/15/25 4:05:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $TIVC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tivic Health Systems Inc.

    SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

    5/15/24 4:47:23 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Tivic Health Systems Inc. (Amendment)

    SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

    2/9/24 4:05:08 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Tivic Health Systems Inc. (Amendment)

    SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

    2/1/24 9:01:29 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care